In another cohort of 60 diffuse large b-cell lymphoma (DLBCL) patients, 37% of patients who developed bacterial infections after day 30 had documented bacterial infections between days 0 and 30 after CD19-directed therapy (12). The gene discussed is CD19; the disease is bacterial infectious disease.